FDA faces backlash after seeking more data on an experimental ALS therapy

FDA faces backlash after seeking more data on an experimental ALS therapy

Source: 
BioPharma Dive
snippet: 

Among the new drugs in development, one of the most closely watched comes from Amylyx Pharmaceuticals, a Cambridge, Massachusetts-based company. Last year, results from a small study showed patients treated with Amylyx's drug, known as AMX0035, appeared to do modestly better at performing essential functions like speaking, walking and writing compared to those who got a placebo. The study also found patients had slower functional declines and lived longer after receiving AMX0035.